GlassScriptPhysician profile
Brian J Sutterer
NPI 1720519184
$818.94
in general payments reported to CMS, 2019-2025
10 companies · $652 in 2025
The $652 reported for 2025 was more than what 86% of Sports Medicine (Internal Medicine) providers received nationally (typical 2025 total: $99.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $33.52 · 2024: $133 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $474 · Food and Beverage: $345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $474.00 |
| Food and Beverage | $344.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eko Health, INC. | $474.00 | 2025 | |
| Elite Orthopedics, LLC | $140.32 | 2023-2025 | |
| Vertex Pharmaceuticals Incorporated | $38.01 | 2025 | |
| Solventum Corporation | $28.29 | 2025 | Prevena Restor Bellaform |
| Depuy Synthes Sales INC. | $26.30 | 2025 | Monovisc |
| Amgen INC. | $25.73 | 2024 | Prolia, Evenity |
| Acera Surgical, INC. | $23.97 | 2025 | Restrata Wound Matrix |
| Endo Pharmaceuticals INC. | $22.53 | 2024 | Xiaflex |
| Endo USA, INC. | $22.50 | 2025 | Xiaflex |
| Alexion Pharmaceuticals, INC. | $17.29 | 2024 | Strensiq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Sutterer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.